1.58
-0.045(-2.78%)
Currency In USD
| Previous Close | 1.62 |
| Open | 1.47 |
| Day High | 1.59 |
| Day Low | 1.46 |
| 52-Week High | 3.87 |
| 52-Week Low | 0.39 |
| Volume | 3.26M |
| Average Volume | 18.02M |
| Market Cap | 114.96M |
| PE | -2.05 |
| EPS | -0.77 |
| Moving Average 50 Days | 1.42 |
| Moving Average 200 Days | 0.98 |
| Change | -0.05 |
If you invested $1000 in Rani Therapeutics Holdings, Inc. (RANI) since IPO date, it would be worth $143.18 as of December 04, 2025 at a share price of $1.575. Whereas If you bought $1000 worth of Rani Therapeutics Holdings, Inc. (RANI) shares 3 years ago, it would be worth $199.37 as of December 04, 2025 at a share price of $1.575.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rani Therapeutics to Participate in the Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 9:05 PM GMT
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
GlobeNewswire Inc.
Oct 30, 2025 12:00 PM GMT
SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
GlobeNewswire Inc.
Oct 23, 2025 8:05 PM GMT
SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the